Navigation Links
Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
Date:8/7/2012

LOS ANGELES, Aug. 7, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce its second quarter financial results and give an operational update in a press release to be issued before the market opens on Tuesday, August 14, 2012. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.

Conference Call DetailsTo access the conference call by phone on August 14 at 10:00 a.m. EDT, dial (800) 537-0745 or (253) 237-1142 for international participants.  A telephone replay will be available beginning approximately two hours after the call through August 21, 2012 and may be accessed by dialing (855) 859-2056 or (404) 537-3406.  The conference passcode for both the live call and replay is 18367261.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.responsegenetics.com.  It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.Response Genetics Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's principal customers include oncologists, pathologists and hospitals. In addition to diagnostic testing services, the Company generates revenue from the sale of its analytical testing services of clinical trial specimens to the pharmaceutical industry.  The Company's headquarters is located in Los Angeles, California. For additional information, please visit www.responsegenetics.com.

Forward-Looking Statement NoticeExcept for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into new areas such as companion diagnostics, to continue to execute on its business strategy and operations, to continue to  analyze cancer samples, and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.  

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. Investor Relations Contact:

Media Relations Contact:Peter Rahmer

Barry SudbeckTrout Group

Fleishman-Hillard646-378-2973

415-318-4261


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
2. Market response to Kallo technology
3. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
4. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
5. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
6. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
7. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
8. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
9. Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
10. Alexza Receives Complete Response Letter for Adasuve™ NDA
11. Press Ganey Releases Enhanced Improvement Portal with Customized Performance Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
Breaking Medicine News(10 mins):